West Pharmaceutical Services, Inc.
WST · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B |
| Cost of Revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B | $1.17B |
| Gross Profit | $1.10B | $998.50M | $1.13B | $1.14B | $1.18B | $767.80M | $605.70M | $545.40M |
| Research & Development | $74.30M | $69.10M | $68.40M | $58.50M | $52.80M | $46.90M | $38.90M | $40.30M |
| Selling, General & Administrative | $393.60M | $338.50M | $353.40M | $316.90M | $362.80M | $302.00M | $272.70M | $262.90M |
| Operating Income | $584.90M | $569.90M | $676.00M | $734.00M | $752.30M | $406.90M | $296.60M | $240.30M |
| Interest Expense | $15.10M | $16.20M | $9.00M | $7.90M | $8.20M | $8.20M | $8.50M | $8.40M |
| Other Income / (Expense) | -$1.00M | -$1.00M | $22.00M | -$54.10M | -$3.40M | -$5.60M | -$4.80M | $400.00K |
| Income Before Taxes | $600.90M | $585.50M | $698.00M | $679.90M | $748.90M | $401.30M | $291.80M | $240.70M |
| Provision for Income Taxes | $121.60M | $107.50M | $122.30M | $114.70M | $107.20M | $72.50M | $59.00M | $41.40M |
| Net Income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M | $346.20M | $241.70M | $206.90M |
| Basic EPS | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 | $2.80 |
| Diluted EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 |
| Basic Shares Outstanding | 72.30M | 73.00M | 74.30M | 74.40M | 74.40M | 73.90M | 74.00M | 73.90M |
| Diluted Shares Outstanding | 72.70M | 73.70M | 75.30M | 75.80M | 76.30M | 75.80M | 75.40M | 75.40M |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $9.45 | $9.45 | $9.45 | 1 | ↑1 ↓0 |
| Dec 2027 | $9.94 | $9.38 | $10.50 | 6 | ↑1 ↓1 |
| Dec 2028 | $11.00 | $10.66 | $11.61 | 3 | ↑0 ↓0 |
| Dec 2029 | $11.60 | $11.60 | $11.60 | 1 | ↑0 ↓0 |
